C4 THERAPEUTICS INC's ticker is CCCC and the CUSIP is 12529R107. A total of 84 filers reported holding C4 THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 1.83 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $1 | -96.0% | 320 | -95.9% | 0.00% | – |
| Q1 2023 | $25 | -85.2% | 7,864 | -72.5% | 0.00% | – |
| Q4 2022 | $169 | -99.9% | 28,602 | +0.1% | 0.00% | – |
| Q3 2022 | $251,000 | +16.7% | 28,577 | +0.4% | 0.00% | – |
| Q2 2022 | $215,000 | -68.9% | 28,452 | -0.3% | 0.00% | -100.0% |
| Q1 2022 | $692,000 | -24.6% | 28,541 | +0.1% | 0.00% | 0.0% |
| Q4 2021 | $918,000 | -17.7% | 28,523 | +14.3% | 0.00% | 0.0% |
| Q3 2021 | $1,115,000 | -0.4% | 24,955 | -15.6% | 0.00% | 0.0% |
| Q2 2021 | $1,119,000 | +221.6% | 29,581 | +214.7% | 0.00% | – |
| Q1 2021 | $348,000 | +34.9% | 9,400 | +20.5% | 0.00% | – |
| Q4 2020 | $258,000 | – | 7,800 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| COMMODORE CAPITAL LP | 481,094 | $15,939,000 | 8.67% |
| Bain Capital Life Sciences Investors, LLC | 1,642,209 | $54,406,000 | 3.42% |
| Darwin Global Management, Ltd. | 228,595 | $7,573,000 | 2.11% |
| Asymmetry Capital Management, L.P. | 139,343 | $4,616,000 | 2.10% |
| Cormorant Asset Management, LP | 2,490,065 | $80,021,000 | 1.90% |
| Logos Global Management LP | 477,928 | $15,834,000 | 1.36% |
| SPHERA FUNDS MANAGEMENT LTD. | 443,824 | $14,601,000 | 1.30% |
| Soleus Capital Management, L.P. | 268,548 | $8,897,000 | 1.17% |
| P.A.W. CAPITAL CORP | 40,000 | $1,325,000 | 1.17% |
| RTW INVESTMENTS, LP | 2,149,228 | $68,679,000 | 1.15% |